What pituitary tumours may tell us about the biology of other cancers

July 30, 2012

(Medical Xpress) -- Expression levels of a DNA repair gene called MGMT have been widely studied across many cancers as a biomarker of response to temozolomide, a chemotherapeutic agent. Now Australian scientists have published findings suggesting MGMT may also play a significant role in tumour progression.

Previous work by the same group showed that MGMT was expressed at different levels in pituitary tumours, those with low levels being more aggressive. It is those more aggressive tumours that tend to respond to chemotherapy, because MGMT can no longer undo the damage caused by the drug.

The current study looked closely at 19 pituitary tumours, 12 expressing high levels of MGMT, 7 low, showing very different between the two groups.

Further investigation also revealed very different , or ‘signaling pathways’. The tumours with high MGMT expression showed activation of genes implicated in resistance. Those with low MGMT expression showed activation of genes involved in DNA damage and repair, as well as genes involved in gene transcription.

These results led to the formulation of a model describing the possible role of MGMT in pituitary tumour progression – and the conclusion that the results may apply to many other cancer types.

Endocrinologist Dr Ann McCormack, now at Sydney’s Garvan Institute of Medical Research, undertook much of this work in collaboration with Associate Professor Roderick Clifton-Bligh as part of her doctoral studies at the Kolling Institute of Medical Research. Microarray analysis and Gene Set Enrichment Analysis were done with Dr Warren Kaplan from Garvan. The findings are described in Pituitary, now online.

“Pituitary tumours display a strong tendency towards ‘senescence’, akin to hibernation, and most do not become aggressive or malignant,” said Dr McCormack.

“In a small number of cases, however, the tumours emerge from their senescent state and become aggressive. It is likely that prolonged DNA damage signaling contributes to this progression.”

“This study told us that loss of MGMT expression may contribute to the progressive accumulation of genetic mutations and cellular proliferation that occurs.”

“We feel these results would be of interest to other cancer researchers. There has been substantial literature regarding MGMT as a of response to temozolomide, however, this is the first paper to examine the relationship between MGMT and genome-wide gene expression profiles in any tumour type.”

“We believe that as well as being a biomarker of treatment response, MGMT may ultimately serve to reflect tumour biology and act as a prognostic indicator. These are preliminary findings and we now need to validate our results.”

Explore further: Gene change identifies brain cancer patients that respond better to treatment

Related Stories

Gene change identifies brain cancer patients that respond better to treatment

May 31, 2011
New research proves that a change in a particular gene can identify which patients with a specific kind of brain cancer will respond better to treatment. Testing for the gene can distinguish patients with a more- or less-aggressive ...

Revised glioblastoma classification should improve patient care

May 16, 2012
Radiation oncology researchers have revised the system used by doctors since the 1990s to determine the prognosis of people with glioblastoma, which is the most devastating of malignant brain tumors.

Gene-modified stem cell transplant protects patients from toxic side effects of chemotherapy

May 9, 2012
For the first time, scientists at Fred Hutchinson Cancer Research Center have transplanted brain cancer patients' own gene-modified blood stem cells in order to protect their bone marrow against the toxic side effects of ...

Potential for earlier diagnosis of ovarian cancer

January 25, 2012
(Medical Xpress) -- Australian scientists have identified biochemical changes that commonly occur in the DNA of women with ovarian cancer, which may help diagnose the cancer at an earlier stage in the future.

Recommended for you

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.